Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death
Abstract
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome arising in many contexts. Its underlying mechanisms are often unclear, but defective granule-mediated cytotoxicity (familial HLH) and excess interleukin-18 (IL-18; macrophage activation syndrome) provide clues. Mounting evidence suggests the causes of HLH converge on cytotoxic T lymphocyte (CTL) hyperactivation and interferon gamma (IFN-γ) overproduction. We refined an in vitro system to simultaneously quantify multiple parameters of the murine CTL immune synapse (IS). Even in haploinsufficiency, perforin deficiency prolonged IS duration and increased IFN-γ/tumor necrosis factor production. Similarly, both target cell immortalization and inhibition of apoptotic caspases impaired IS termination and increased cytokine production. Strong CTL activation, through T-cell receptor or IL-18 signaling, also increased IFN-γ secretion but accelerated target cell death. Impaired IS termination synergized with strong CTL activation in driving IFN-γ production. Visually, both typical and Prf1–/– CTL-IS terminated with apoptotic contraction. Serendipitously, we observed many IL-18–exposed CTL-IS terminated by target cell ballooning. Both IL-18–activated CTL and IFN-γ pretreatment caused up to half of target cells to die by receptor-interacting protein kinase 1 (RIPK1)–dependent necroptosis. In vivo, RIPK1 inhibition ameliorated virus-triggered HLH in Il18tg more than Prf1–/– mice. By quantifying CTL-IS duration, cytokine production, and mode of cell death, we modeled multiple HLH contributors and their interactions and identified 3 HLH mechanistic categories: impaired IS termination, intense CTL cytokine production, and inflammatory target cell death. Integrating the inputs and outcomes of a hyperinflammatory CTL-IS may provide a useful framework for understanding, predicting, or treating HLH in its many forms.
Article Details
Authors (9)
Anastasia Frank-Kamenetskii
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA
Hannah Klinghoffer
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA
Jemy Varghese
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA
Vinh Dang
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA
Jeremy Morrissette
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA
Joseph A. Fraietta
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania
Caroline Diorio
Janis K. Burkhardt
7Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Scott W. Canna
1Division of Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, PA